Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers

Human Pathology
Andreas H MarxJakob R Izbicki

Abstract

HER-2 is the molecular target for antibody-based treatment of breast cancer (trastuzumab). The potential benefit of anti-HER-2 therapy is currently investigated in several other HER-2 amplified cancers. For example, trastuzumab was recently shown to be effective in HER-2 positive gastric cancer. To address the potential applicability of anti-HER-2 therapy in colorectal cancer, tissue microarray sections and colorectal resection specimens of 1851 colorectal cancers were analyzed for HER-2 overexpression and amplification using FDA approved reagents for immunohistochemistry and fluorescence in situ hybridization. HER-2 amplification was seen in 2.5% and HER-2 overexpression in 2.7% of 1439 interpretable colorectal cancers. Amplification was often high level with HER-2 copies ranging from 4 to 60 per tumor cell and was strongly related to protein overexpression. HER-2 amplification and overexpression were unrelated to histological tumor type, tumor localization, grading, pT, pN, pM or survival. As heterogeneity of drug target expression could represent a major drawback for targeted cancer therapy we next studied HER-2 heterogeneity in selected cases. Extensive evaluation of all available large sections from patients with HER-2 pos...Continue Reading

References

Aug 2, 2001·Journal of the National Cancer Institute·R SimonG Sauter
May 27, 2003·International Journal of Cancer. Journal International Du Cancer·Daniel R NathansonPhilip B Paty
May 15, 2004·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Akishi OoiYoh Dobashi
Jun 24, 2005·Nature Methods·David L Rimm
Jul 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Federico CappuzzoFred R Hirsch
Jun 29, 2006·The Cancer Journal·Panteleimon KountourakisTheofanis Economopoulos
Sep 2, 2006·International Journal of Colorectal Disease·Dong Il ParkAntonia R Sepulveda
Dec 5, 2006·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Uta ReicheltGuido Sauter
Mar 16, 2007·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Coya TapiaGuido Sauter
Sep 27, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V AdamoA Russo
Nov 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Laurent ArnouldBruno P Coudert
Dec 23, 2008·Histopathology·A G AntonacopoulouH P Kalofonos
Jan 3, 2009·BMC Cancer·Dara O KavanaghIqdam Tobbia
Feb 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido SauterMichael F Press
Mar 10, 2009·Human Pathology·Andreas H MarxGuido Sauter

❮ Previous
Next ❯

Citations

Aug 18, 2012·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Tobias J GrobWaldemar Wilczak
Jan 26, 2013·International Journal of Molecular Sciences·Giuseppe AprileStefano Pizzolitto
Apr 16, 2014·International Journal of Colorectal Disease·Enken DrecollRupert Langer
Sep 12, 2014·British Journal of Cancer·B Ingold HeppnerC Röcken
Nov 25, 2014·BMC Cancer·Keigo MitsuiChoitsu Sakamoto
Jan 19, 2016·Future Oncology·Daniel H Ahn, Richard M Goldberg
May 28, 2014·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Eike BurandtWaldemar Wilczak
Oct 16, 2012·International Journal of Cancer. Journal International Du Cancer·Pierre TennstedtKerstin Borgmann
Apr 17, 2016·Critical Reviews in Oncology/hematology·Wen XuJermaine I G Coward
Oct 15, 2013·Genes, Chromosomes & Cancer·Natalia Buza, Pei Hui
Oct 10, 2015·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Emanuele ValtortaMarcello Gambacorta
May 28, 2011·The Lancet Oncology·Linda E Kelemen, Martin Köbel
Jun 1, 2015·Pathology Oncology Research : POR·Phillip R StahlAlexander Quaas
Dec 3, 2014·Experimental and Therapeutic Medicine·Jinhua TuShunping Chen
Mar 1, 2018·Current Treatment Options in Oncology·Michael LamScott Kopetz
Aug 11, 2018·Expert Review of Anticancer Therapy·Imane El Dika, David H Ilson
Oct 7, 2019·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·G WangY Pan
Jun 2, 2015·Arkhiv patologii·D S KobyakovL M Nepomnyaschikh
May 16, 2019·International Journal of Cancer. Journal International Du Cancer·Naoki TakegawaKazuhiko Nakagawa
Aug 1, 2020·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Bo WangXiaoling Wang
May 2, 2019·World Journal of Gastrointestinal Oncology·Xin-Yu WangDeng-Feng Cao
Aug 1, 2015·World Journal of Gastroenterology : WJG·Wen-Juan YangMei Yuan
Jul 17, 2018·Gastroenterology Research and Practice·Gianluca PellinoFrancesco Selvaggi
May 6, 2021·International Journal of Molecular Sciences·Alice IndiniFrancesco Grossi
Jun 17, 2021·Expert Review of Anticancer Therapy·Zhiqin ChenMing Quan
Jul 3, 2021·International Journal of Molecular Sciences·Chiara GuariniCamillo Porta

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

© 2021 Meta ULC. All rights reserved